AMGN posts
FeedPosted Jan 4th 2011 11:00AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, eBay (EBAY), Motorola (MOT), Walgreen Co (WAG), Carnival Corp (CCL), Safeway Inc (SWY), NIKE, Inc'B' (NKE), QUALCOMM Inc (QCOM), Amgen Inc (AMGN), Analyst Initiations, Polo Ralph Lauren'A' (RL)
Analyst Upgrades
- Polo Ralph Lauren (RL) to buy from hold at Citigroup.
- Qualcomm (QCOM) to buy from neutral at Roth Capital.
- Walgreen (WAG) to conviction buy from neutral at Goldman.
- Rockwell (ROK) to outperform from neutral at Credit Suisse.
- Carnival (CCL) to buy from hold at Deutsche Bank.
- SunTrust (STI) and TD Bank (TD) to outperform from market perform at Keefe Bruyette.
- Hawaiian Electric (HE) to outperform from neutral at RW Baird.
- Essex Property Trust (ESS) to outperform from neutral at Macquarie.
- Amgen (AMGN) to neutral from underperform at BofA/Merrill.
Continue reading Analyst Calls: EBAY, ERIC, MMI, MSI, NKE, QCOM, RL, ROK, SWY, WAG ...
Posted Dec 14th 2010 4:20PM by Jon Ogg (RSS feed)
Filed under: Best Buy (BBY), BP p.l.c. ADS (BP), Amgen Inc (AMGN)

Markets were mixed into the closing bell today and down to the wire as indexes fluctuated between positive and negative. The FOMC kept rates at zero and committed to ongoing quantitative easing measures, which includes reinvesting monies coming in from its existing securities portfolio. Retail and electronics were weak based on an
earnings disappointment.
Here were today's unofficial closing bell levels:
Dow Jones 11,476.62 +48.06 (0.42%)
S&P 500 1,241.58 +1.12 (0.09%)
Nasdaq 2,627.72 +2.81 (0.11%)
Top Analyst Upgrades & DowngradesContinue reading Closing Bell: FOMC Meets Equity Unease (AMGN, BBY, BP, GXDX, OXPS, VECO)
Posted Dec 14th 2010 11:30AM by Elizabeth Harrow (RSS feed)
Filed under: Major Movement, Analyst Upgrades and Downgrades, Amgen Inc (AMGN), Technical Analysis
Late Monday, Amgen (AMGN) unveiled positive results for its bone drug, denosumab. A clinical study of 1,432 men with hormone refractory prostate cancer revealed that denosumab, which is also known as Xgeva, improved bone metastasis-free survival by 4.2 months. However, the overall survival rate was comparable to a placebo group.
Denosumab is already used to treat osteoporosis under the brand name Prolia, and has been approved under the brand name Xgeva for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. The drug has not yet been approved for the prevention of SREs in multiple myeloma patients.
Continue reading Amgen Boosted by Upbeat Drug Data
Posted Dec 14th 2010 11:00AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Walgreen Co (WAG), Comcast Cl'A' (CMCSA), Research in Motion (RIMM), Amgen Inc (AMGN), Analyst Initiations
Analyst Upgrades
- Amgen (AMGN) to overweight from neutral at Piper Jaffray.
- Goodrich Petroleum (GDP) to outperform from market perform at Wells Fargo.
- Tutor Perini (TPC) to buy from neutral at UBS.
- Covidien (COV) to buy from neutral at Goldman.
- Sara Lee (SLE) and Comcast (CMCSA) to outperform from market perform at Bernstein.
- Research In Motion (RIMM) to outperform from sector perform at FBN Securities.
Continue reading Analyst Calls: AMGN, CMCSA, GDP, FAST, FLR, KBR, PGR, RIMM, SLE, WAG ...
Posted Nov 4th 2010 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Apple Inc (AAPL), Boston Scientific (BSX), Amgen Inc (AMGN), Analyst Initiations, EOG Resources (EOG), Garmin Ltd (GRMN)
Analyst Upgrades
- Goldman upgraded Jones Lang LaSalle (JLL) to buy from neutral.
- Credit Suisse upgraded Pulte Group (PHM) to neutral from underperform. Note that Citigroup downgraded the stock.
- Ameristar Casinos (ASCA) was upgraded to neutral from sell at Merriman.
- Citigroup upgraded Kimco Realty (KIM) to hold from sell.
- Mistras (MG) was upgraded to buy from hold at KeyBanc.
- Devon Energy (DVN) was upgraded to outperform from neutral at Macquarie.
- Garmin (GRMN) was upgraded to outperform from sector perform at PacCrest.
Continue reading Analyst Calls: AAPL, AMGN, BIIB, BSX, CHK, DVN, EOG, GRMN, PHM, WPO ...
Posted Sep 14th 2010 12:00PM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Exxon Mobil (XOM), Campbell Soup (CPB), Newell Rubbermaid (NWL), Amgen Inc (AMGN), Analyst Initiations
Analyst Upgrades
- Soleil upgraded Hologic (HOLX) to buy from hold on expectations the company's next-generation breast tomosynthesis instrument is likely to receive FDA approval. The firm raised its target price for shares to $20 from $16.
- ING Group upgraded Total (TOT) to buy from hold.
- BofA/Merrill raised Medicis (MRX) to neutral from underperform.
- CPFL Energia (CPL) was upgraded to buy from hold at Deutsche Bank.
Continue reading Analyst Calls: AMGN, ARST, CPB, FE, GMAN, HOLX, NWL, TOT, XOM ...
Posted Sep 9th 2010 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, American Express (AXP), BB and T (BBT), Research in Motion (RIMM), Analyst Initiations, Teva Pharm Indus ADR (TEVA), Gilead Sciences (GILD), Lloyds TSB Group plc ADS (LYG)
Analyst Upgrades
- Oppenheimer upgraded Teva (TEVA) to outperform from perform. The firm expects the company to generate strong 2H10 earnings and thinks the competition created by Novartis's (NVS) Gilenia will be limited.
- Citigroup upgraded Celanese (CE) to buy from hold, citing valuation and the company's move to add assets in China, as well as possible takeover interest.
- Needham raised Stereotaxis (STXS) to buy from hold as the firm thinks that strong clinical data recently announced by the company could result in faster adoption rates of its robotic surgery.
- BMO Capital upgraded Smurfit-Stone Container (SSCC) given strength in the containerboard market.
- Melco Crown (MPEL) was upgraded to buy from neutral at UBS.
- Goldman Sachs raised Temple-Inland (TIN) to buy from neutral.
- Barclays upgraded Lloyds Banking (LYG) to equal weight from underweight.
Continue reading Analyst Calls: AMGN, APOL, CE, CELG, HGSI, RIMM, STXS, SUN, TEVA, VAL ...
Posted Aug 16th 2010 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Analyst Initiations, Gilead Sciences (GILD), Genzyme (GENZ)
Analyst Upgrades
- Deutsche Bank upgraded Smurfit-Stone (SSCC) to buy from hold after raising its estimates for containerboard names and upped its target for shares to $28 from $22. The firm also raised its price target for International Paper (IP) to $38 from $32, for Packaging Corp. (PKG) to $33 from $28, for Temple-Inland (TIN) to $31 from $28, for Greif (GEF) to $67 from $65, and for Rock-Tenn (RKT) to $70 from $65. All stocks are buy rated.
- ThinkEquity upgraded VMware (VMW) to buy from hold and has a $90 price target on the stock. The firm expects VMware to benefit from increased virtual infrastructure adoption and improving vSphere solutions.
- Needham upgraded Cavium Networks (CAVM) to strong buy from buy, citing the recent pullback in shares following Cisco's (CSCO) cautious commentary. The firm has a $37 target on the stock.
- Intercontinental Exchange (ICE) was upgraded to outperform from neutral at Credit Suisse.
- MedAssets (MDAS) was upgraded to buy from hold at Auriga.
- Brookfield Properties (BPO) was upgraded to buy from hold at Citigroup.
Continue reading Analyst Calls: AMGN, CAVM, COCO, GENZ, GILD, ICE, PWRD, SSCC, VMW ...
Posted Mar 21st 2010 1:00PM by Michael Shulman (RSS feed)
Filed under: Amgen Inc (AMGN), Stocks to Sell
A lot of investors think Amgen (AMGN) is a great next-generation biotech company. Wrong. Amgen was a decent last-generation biotech company.
It's terribly managed outfit living on EPO drugs for dialysis and oncology patients. True, it has a billion dollar (actually more) drug, Neupogen, but it could be subject to generic competition in the United States from TEVA within two years.
Continue reading Deadbeat Stock #6: Amgen (AMGN)
Next Page >